Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma
Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the drug erlotinib (erlotinib hydrochloride) in people
with malignant peritoneal mesothelioma who have a specific genetic mutation in their cancer.
Erlotinib has been approved by the United States Food and Drug Administration (FDA) for other
cancers, but erlotinib has not been approved for malignant peritoneal mesothelioma. This
research is being done because there is no current standard treatment for malignant
peritoneal mesothelioma and the study doctors want to see how erlotinib affects malignant
peritoneal mesothelioma.